Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
Details for the poster presentations are as follows:
ONC201: Characterization and combinatorial efficacy in brain tumors
Title: ADME and toxicology profiles of first-in-class DRD2/ClpP-targeted imipridone ONC201
Abstract Number: 1370
Date and Time:
Presenter:
Session Title: Pharmacology, Pharmacogenetics, and Pharmacogenomics
Title: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG)
Abstract Number: 635
Date and Time:
Presenter:
Session Title: Pediatric Cancer: Clinical Investigations
Title: The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell lines
Abstract Number: 1156
Date and Time:
Presenter:
Session Title: HDAC and Methyltransferase Inhibitors
ONC201: Combinatorial efficacy in other solid tumors
Title: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death
Abstract Number: 1060
Date and Time:
Presenter: Wen-I Chang, M.D.,
Session Title: Combination Therapies
Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors of apoptosis and up-regulation of DR5 in gastric adenocarcinoma
Abstract Number: 1044
Date and Time:
Presenter:
Session Title: Combination Therapies
Title: Imipridones exhibit synergy with sorafenib, HDAC inhibition, PARP inhibition, and proteasome inhibition in liver cancer cell lines
Abstract Number: 1040
Date and Time:
Presenter:
Session Title: Combination Therapies
ONC206: Mechanism of action and biomarkers
Title: Predictive Biomarker Evaluation and Molecular Differentiation for Imipridones ONC201 and ONC206
Abstract Number: 393
Date and Time:
Presenter:
Session Title: Biomarkers Predictive of Therapeutic Benefit
Title: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell response
Abstract Number: 1440
Date and Time:
Presenter:
Session Title: Role of Microenvironment in therapeutic response
ONC212: Efficacy in pancreatic cancer
Title: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines
Abstract Number: 1006
Date and Time:
Presenter:
Session Title: Cellular Responses to Anticancer Drugs
Title: ONC212-induced impairment of oxidative phosphorylation is synergistic with glycolysis inhibition in treatment of pancreatic cancer in vitro and in vivo
Abstract Number: 2329
Date and Time:
Presenter:
Session Title: Metabolic Pathways
Posters will be available for registered attendees on the AACR website on
About Chimerix
CONTACT:
Investor Relations:
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Source: Chimerix, Inc.